GSK 933776

Drug Profile

GSK 933776

Alternative Names: 933776; Alzheimer's disease vaccine - GlaxoSmithKline; GSK-933776A

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Dry age-related macular degeneration

Most Recent Events

  • 29 Jul 2015 Phase-II clinical trials in Alzheimer's disease in Sweden, Australia, Germany, Norway (IV)
  • 21 Jul 2015 Phase-II development for Dry age-related macular degeneration is ongoing in Canada and USA
  • 01 Jul 2014 GlaxoSmithKline completes a phase I pharmacokinetic trial of GSK 933776 (SC, IM, IV) in healthy volunteers in USA (NCT02033668)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top